Article
Licensed
Unlicensed
Requires Authentication
Editorial
-
Tade Matthias Spranger
Published/Copyright:
September 9, 2005
Abstract
Since the Cartagena Protocol on Biosafety came into force, the establishment of national regulatory schemes became one of the most important biosafety issues. Glen Kurokawa and Darryl Macer provide pivotal information about the current legal situation in Southern and Southeastern Asia, i.e. Bangladesh, Bhutan, Brunei, Cambodia, PR China, India, Indonesia, Laos, Malaysia, Myanmar, Nepal, the Philippines, Singapore, Sri Lanka, Thailand, Timor Leste, and Vietnam.
:
Published Online: 2005-09-09
Published in Print: 2005-09-07
Walter de Gruyter GmbH & Co. KG
You are currently not able to access this content.
You are currently not able to access this content.
Articles in the same Issue
- Editorial
- Biosafety Regulation Trends in Southern and Southeastern Asia
- Property in a Human Body: A Common Law Approach
- Pharmacogenomics: An In-House Advantage?
- The German Way of Dealing with “The Tragedy of the Anticommons” – Purpose-Bound Protection for Product Patents on Genetic Information in Germany
- Pharmacogenomics and Data Protection
- Development and Implications of Patent Law
- Life Sciences and Biotechnology
- Declaration on Human Cloning
- Gene Therapy in PR China: Regulations and Ethical Concerns
- Biotechnological Potential of Marine Sponges and their Associated Bacteria as Producers of New Pharmaceuticals (Part I)
Articles in the same Issue
- Editorial
- Biosafety Regulation Trends in Southern and Southeastern Asia
- Property in a Human Body: A Common Law Approach
- Pharmacogenomics: An In-House Advantage?
- The German Way of Dealing with “The Tragedy of the Anticommons” – Purpose-Bound Protection for Product Patents on Genetic Information in Germany
- Pharmacogenomics and Data Protection
- Development and Implications of Patent Law
- Life Sciences and Biotechnology
- Declaration on Human Cloning
- Gene Therapy in PR China: Regulations and Ethical Concerns
- Biotechnological Potential of Marine Sponges and their Associated Bacteria as Producers of New Pharmaceuticals (Part I)
